Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings press release available on the company's website. We are transforming Certara into a company we believe is capable of delivering sustainable double-digit growth. The macro market conditions, biopharma spending, clinical trial starts, and new regulatory guidance continue to be in our favor. Top-line results in the quarter were in line with expectations and guidance.
Overall, revenue growth was modest at 1%, with software revenue growing 4% and service revenue declining 3%. On software, a renewed focus on driving new growth is building momentum. Normalizing for the Chemaxon acquisition, trailing 12-month bookings grew 7% exiting the first half, up sharply from 0.8% exiting 2025. Overall, software revenue now represents 53% of our business versus 40% just two years ago.
Our pipeline grew 27% year-over-year exiting the quarter, which we anticipate translating into revenue growth in the back half of 2026. Today, we are reaffirming our guidance range of 0% to 4% for full-year revenue growth. Shifting to the key actions we have taken to improve our ability to drive growth. May divestiture was our first step in sharpening our strategy, rebalancing Certara, improving our overall financial predictability, and strengthening our software services flywheel.